The Transcription Factor SLUG may Drive the Progression of Akt and HER2/neu

转录因子 SLUG 可能驱动 Akt 和 HER2/neu 的进展

• 批准号: 7847272
• 负责人: DENNIS J SLAMON
• 金额: $ 3.81万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7847272
• 关键词: African American; Antibodies; Biological Factors; Biological Markers; Biological Testing; Biotechnology; Breast; Breast Cancer Cell; Cancer Center; Cancer Patient; Cancer cell line; Candidate Disease Gene; Cell Adhesion Molecules; Cell Line; Cell model; Cell-Cell Adhesion; Cells; Clinical; Clinical Trials; Cohort Studies; Cultured Cells; Data; Disease; Disease Outcome; Disease-Free Survival; Doctor of Medicine; Doctor of Philosophy; Down-Regulation; Drug resistance; E-Cadherin; ERBB2 gene; Economic Factors; Epithelial; Epithelial Cells; Ethnic Origin; Family; Freezing; Future; Gene Proteins; Genes; Growth; Hispanics; In Vitro; Insurance; Laboratories; Latina; Lead; MCF7 cell; Malignant Neoplasms; Mammary Neoplasms; Mammary gland; Medical; Mentors; Mesenchymal; Messenger RNA; Methods; Microarray Analysis; Minority; Modeling; Molecular Target; Names; Neoplasm Metastasis; Normal Cell; Outcome; Outcome Study; PTEN gene; Paraffin; Pathogenesis; Pathway interactions; Patients; Play; Population; Postdoctoral Fellow; Predictive Value; Principal Investigator; Race; Recurrence; Regulation; Research; Research Design; Research Personnel; Resistance; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; Roche brand of trastuzumab; Role; SKBR3; Salmon; Sample Size; Sampling; Scientist; Signal Pathway; Signal Transduction; Site; Slide; Small Interfering RNA; Snails; Specificity; System; Testing; Therapeutic Intervention; Time; Tissues; Transfection; Transgenic Mice; Trastuzumab; Tumor Subtype; Tumor Tissue; Underrepresented Minority; Underserved Population; Universities; Up-Regulation; Woman; abstracting; cancer health disparity; cancer stem cell; cell motility; chemotherapy; clinically significant; epithelial to mesenchymal transition; erbB-2 Receptor; established cell line; experience; health care quality; improved; in vitro Model; in vivo; inhibitor/antagonist; interest; malignant breast neoplasm; mortality; mouse model; neoplastic cell; novel; overexpression; prevent; prognostic; receptor; repository; response; self-renewal; slug; stem cell differentiation; therapy resistant; tissue culture; transcription factor; tumor; tumor progression; wortmannin